A new study has been launched to identify factors which may influence how patients or prescribers feel about taking or administering a new innovative treatment for respiratory infections. The study is part of the FAIR project, which is funded by Horizon 2020.
Flagellin is a complimentary product to antibiotics, designed to be administered as an aerosol. Through this study, the researchers hope to be able to identify if there are any negative factors which might discourage patients from using it or clinicians from administering it. Survey responses from both sides will help to identify how this treatment could be adapted to meet user needs.
There are two separate surveys available – one for clinicians and one for patients. Both are available in English and French. The surveys consist only of questionnaires and there is no actual use of this treatment as part of the study. The study will gather feedback based on a hypothetical scenario.